leish-f3 + sla-se
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02071758)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- LeishmaniaImmunity, active
Leishmania immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- leish-f3 + sla-se
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02071758 | Phase 1 | Apr 1, 2014 | Bill and Melinda Gates Foundation, Immune Design, Infectious Disease Research Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Immune Design | For profit | 1 | 0 | 1 | 2014 |
| Infectious Disease Research Institute | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1